Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer

Lung cancer is one of the most prevalent malignancies with the highest morbidity and mortality rates worldwide. In recent years, with the development of immune-oncology research and several therapeutic antibodies have reach the clinic, many breakthroughs have been made in immunotherapy. The advent o...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Chang JIANG [verfasserIn] Ling YI [verfasserIn] Xiang GAO [verfasserIn] Hongtao ZHANG [verfasserIn] Shucai ZHANG [verfasserIn]

Format:	E-Artikel
Sprache:	Chinesisch

Erschienen:	2022

Schlagwörter:	nsclc immunotherapy biomarker pd-l1 tmb

Übergeordnetes Werk:	In: Chinese Journal of Lung Cancer - Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2008, 25(2022), 1, Seite 46-53
Übergeordnetes Werk:	volume:25 ; year:2022 ; number:1 ; pages:46-53

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.3779/j.issn.1009-3419.2021.102.55

Katalog-ID:	DOAJ073516902

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ073516902
003	DE-627
005	20230309115427.0
007	cr uuu---uuuuu
008	230228s2022 xx \|\|\|\|\|o 00\| \|\|chi c
024	7		\|a 10.3779/j.issn.1009-3419.2021.102.55 \|2 doi
035			\|a (DE-627)DOAJ073516902
035			\|a (DE-599)DOAJ78ea8da0f1b947d2bfeea8b357218deb
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a chi
050		0	\|a RC254-282
100	0		\|a Chang JIANG \|e verfasserin \|4 aut
245	1	0	\|a Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Lung cancer is one of the most prevalent malignancies with the highest morbidity and mortality rates worldwide. In recent years, with the development of immune-oncology research and several therapeutic antibodies have reach the clinic, many breakthroughs have been made in immunotherapy. The advent of immunotherapy has revolutionized the treatment of NSCLC, but the response and durable clinical benefit are only observed in a small subset of patients. Therefore, strategies to screen the potential beneficial population and improve the efficacy of immunotherapy remain an essential topic. In the current article, the author review the biomarkers that have potential to better predict responders to immunotherapy and to provide ideas for the clinical application of immunotherapy.
650		4	\|a nsclc
650		4	\|a immunotherapy
650		4	\|a biomarker
650		4	\|a pd-l1
650		4	\|a tmb
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Ling YI \|e verfasserin \|4 aut
700	0		\|a Xiang GAO \|e verfasserin \|4 aut
700	0		\|a Hongtao ZHANG \|e verfasserin \|4 aut
700	0		\|a Shucai ZHANG \|e verfasserin \|4 aut
773	0	8	\|i In \|t Chinese Journal of Lung Cancer \|d Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2008 \|g 25(2022), 1, Seite 46-53 \|w (DE-627)572421125 \|w (DE-600)2438672-8 \|x 19996187 \|7 nnns
773	1	8	\|g volume:25 \|g year:2022 \|g number:1 \|g pages:46-53
856	4	0	\|u https://doi.org/10.3779/j.issn.1009-3419.2021.102.55 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/78ea8da0f1b947d2bfeea8b357218deb \|z kostenfrei
856	4	0	\|u http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.55 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1009-3419 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1999-6187 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 25 \|j 2022 \|e 1 \|h 46-53

Indexfelder

author_variant	c j cj l y ly x g xg h z hz s z sz
matchkey_str	article:19996187:2022----::eerhrgesfmuohrpboakrfros
hierarchy_sort_str	2022
callnumber-subject-code	RC
publishDate	2022
allfields	10.3779/j.issn.1009-3419.2021.102.55 doi (DE-627)DOAJ073516902 (DE-599)DOAJ78ea8da0f1b947d2bfeea8b357218deb DE-627 ger DE-627 rakwb chi RC254-282 Chang JIANG verfasserin aut Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Lung cancer is one of the most prevalent malignancies with the highest morbidity and mortality rates worldwide. In recent years, with the development of immune-oncology research and several therapeutic antibodies have reach the clinic, many breakthroughs have been made in immunotherapy. The advent of immunotherapy has revolutionized the treatment of NSCLC, but the response and durable clinical benefit are only observed in a small subset of patients. Therefore, strategies to screen the potential beneficial population and improve the efficacy of immunotherapy remain an essential topic. In the current article, the author review the biomarkers that have potential to better predict responders to immunotherapy and to provide ideas for the clinical application of immunotherapy. nsclc immunotherapy biomarker pd-l1 tmb Neoplasms. Tumors. Oncology. Including cancer and carcinogens Ling YI verfasserin aut Xiang GAO verfasserin aut Hongtao ZHANG verfasserin aut Shucai ZHANG verfasserin aut In Chinese Journal of Lung Cancer Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2008 25(2022), 1, Seite 46-53 (DE-627)572421125 (DE-600)2438672-8 19996187 nnns volume:25 year:2022 number:1 pages:46-53 https://doi.org/10.3779/j.issn.1009-3419.2021.102.55 kostenfrei https://doaj.org/article/78ea8da0f1b947d2bfeea8b357218deb kostenfrei http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.55 kostenfrei https://doaj.org/toc/1009-3419 Journal toc kostenfrei https://doaj.org/toc/1999-6187 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2014 GBV_ILN_2106 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 25 2022 1 46-53
spelling	10.3779/j.issn.1009-3419.2021.102.55 doi (DE-627)DOAJ073516902 (DE-599)DOAJ78ea8da0f1b947d2bfeea8b357218deb DE-627 ger DE-627 rakwb chi RC254-282 Chang JIANG verfasserin aut Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Lung cancer is one of the most prevalent malignancies with the highest morbidity and mortality rates worldwide. In recent years, with the development of immune-oncology research and several therapeutic antibodies have reach the clinic, many breakthroughs have been made in immunotherapy. The advent of immunotherapy has revolutionized the treatment of NSCLC, but the response and durable clinical benefit are only observed in a small subset of patients. Therefore, strategies to screen the potential beneficial population and improve the efficacy of immunotherapy remain an essential topic. In the current article, the author review the biomarkers that have potential to better predict responders to immunotherapy and to provide ideas for the clinical application of immunotherapy. nsclc immunotherapy biomarker pd-l1 tmb Neoplasms. Tumors. Oncology. Including cancer and carcinogens Ling YI verfasserin aut Xiang GAO verfasserin aut Hongtao ZHANG verfasserin aut Shucai ZHANG verfasserin aut In Chinese Journal of Lung Cancer Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2008 25(2022), 1, Seite 46-53 (DE-627)572421125 (DE-600)2438672-8 19996187 nnns volume:25 year:2022 number:1 pages:46-53 https://doi.org/10.3779/j.issn.1009-3419.2021.102.55 kostenfrei https://doaj.org/article/78ea8da0f1b947d2bfeea8b357218deb kostenfrei http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.55 kostenfrei https://doaj.org/toc/1009-3419 Journal toc kostenfrei https://doaj.org/toc/1999-6187 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2014 GBV_ILN_2106 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 25 2022 1 46-53
allfields_unstemmed	10.3779/j.issn.1009-3419.2021.102.55 doi (DE-627)DOAJ073516902 (DE-599)DOAJ78ea8da0f1b947d2bfeea8b357218deb DE-627 ger DE-627 rakwb chi RC254-282 Chang JIANG verfasserin aut Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Lung cancer is one of the most prevalent malignancies with the highest morbidity and mortality rates worldwide. In recent years, with the development of immune-oncology research and several therapeutic antibodies have reach the clinic, many breakthroughs have been made in immunotherapy. The advent of immunotherapy has revolutionized the treatment of NSCLC, but the response and durable clinical benefit are only observed in a small subset of patients. Therefore, strategies to screen the potential beneficial population and improve the efficacy of immunotherapy remain an essential topic. In the current article, the author review the biomarkers that have potential to better predict responders to immunotherapy and to provide ideas for the clinical application of immunotherapy. nsclc immunotherapy biomarker pd-l1 tmb Neoplasms. Tumors. Oncology. Including cancer and carcinogens Ling YI verfasserin aut Xiang GAO verfasserin aut Hongtao ZHANG verfasserin aut Shucai ZHANG verfasserin aut In Chinese Journal of Lung Cancer Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2008 25(2022), 1, Seite 46-53 (DE-627)572421125 (DE-600)2438672-8 19996187 nnns volume:25 year:2022 number:1 pages:46-53 https://doi.org/10.3779/j.issn.1009-3419.2021.102.55 kostenfrei https://doaj.org/article/78ea8da0f1b947d2bfeea8b357218deb kostenfrei http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.55 kostenfrei https://doaj.org/toc/1009-3419 Journal toc kostenfrei https://doaj.org/toc/1999-6187 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2014 GBV_ILN_2106 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 25 2022 1 46-53
allfieldsGer	10.3779/j.issn.1009-3419.2021.102.55 doi (DE-627)DOAJ073516902 (DE-599)DOAJ78ea8da0f1b947d2bfeea8b357218deb DE-627 ger DE-627 rakwb chi RC254-282 Chang JIANG verfasserin aut Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Lung cancer is one of the most prevalent malignancies with the highest morbidity and mortality rates worldwide. In recent years, with the development of immune-oncology research and several therapeutic antibodies have reach the clinic, many breakthroughs have been made in immunotherapy. The advent of immunotherapy has revolutionized the treatment of NSCLC, but the response and durable clinical benefit are only observed in a small subset of patients. Therefore, strategies to screen the potential beneficial population and improve the efficacy of immunotherapy remain an essential topic. In the current article, the author review the biomarkers that have potential to better predict responders to immunotherapy and to provide ideas for the clinical application of immunotherapy. nsclc immunotherapy biomarker pd-l1 tmb Neoplasms. Tumors. Oncology. Including cancer and carcinogens Ling YI verfasserin aut Xiang GAO verfasserin aut Hongtao ZHANG verfasserin aut Shucai ZHANG verfasserin aut In Chinese Journal of Lung Cancer Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2008 25(2022), 1, Seite 46-53 (DE-627)572421125 (DE-600)2438672-8 19996187 nnns volume:25 year:2022 number:1 pages:46-53 https://doi.org/10.3779/j.issn.1009-3419.2021.102.55 kostenfrei https://doaj.org/article/78ea8da0f1b947d2bfeea8b357218deb kostenfrei http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.55 kostenfrei https://doaj.org/toc/1009-3419 Journal toc kostenfrei https://doaj.org/toc/1999-6187 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2014 GBV_ILN_2106 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 25 2022 1 46-53
allfieldsSound	10.3779/j.issn.1009-3419.2021.102.55 doi (DE-627)DOAJ073516902 (DE-599)DOAJ78ea8da0f1b947d2bfeea8b357218deb DE-627 ger DE-627 rakwb chi RC254-282 Chang JIANG verfasserin aut Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Lung cancer is one of the most prevalent malignancies with the highest morbidity and mortality rates worldwide. In recent years, with the development of immune-oncology research and several therapeutic antibodies have reach the clinic, many breakthroughs have been made in immunotherapy. The advent of immunotherapy has revolutionized the treatment of NSCLC, but the response and durable clinical benefit are only observed in a small subset of patients. Therefore, strategies to screen the potential beneficial population and improve the efficacy of immunotherapy remain an essential topic. In the current article, the author review the biomarkers that have potential to better predict responders to immunotherapy and to provide ideas for the clinical application of immunotherapy. nsclc immunotherapy biomarker pd-l1 tmb Neoplasms. Tumors. Oncology. Including cancer and carcinogens Ling YI verfasserin aut Xiang GAO verfasserin aut Hongtao ZHANG verfasserin aut Shucai ZHANG verfasserin aut In Chinese Journal of Lung Cancer Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2008 25(2022), 1, Seite 46-53 (DE-627)572421125 (DE-600)2438672-8 19996187 nnns volume:25 year:2022 number:1 pages:46-53 https://doi.org/10.3779/j.issn.1009-3419.2021.102.55 kostenfrei https://doaj.org/article/78ea8da0f1b947d2bfeea8b357218deb kostenfrei http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.55 kostenfrei https://doaj.org/toc/1009-3419 Journal toc kostenfrei https://doaj.org/toc/1999-6187 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2014 GBV_ILN_2106 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 25 2022 1 46-53
language	Chinese
source	In Chinese Journal of Lung Cancer 25(2022), 1, Seite 46-53 volume:25 year:2022 number:1 pages:46-53
sourceStr	In Chinese Journal of Lung Cancer 25(2022), 1, Seite 46-53 volume:25 year:2022 number:1 pages:46-53
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	nsclc immunotherapy biomarker pd-l1 tmb Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	Chinese Journal of Lung Cancer
authorswithroles_txt_mv	Chang JIANG @@aut@@ Ling YI @@aut@@ Xiang GAO @@aut@@ Hongtao ZHANG @@aut@@ Shucai ZHANG @@aut@@
publishDateDaySort_date	2022-01-01T00:00:00Z
hierarchy_top_id	572421125
id	DOAJ073516902
language_de	chinesisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ073516902</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309115427.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2022 xx \|\|\|\|\|o 00\| \|\|chi c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3779/j.issn.1009-3419.2021.102.55</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ073516902</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ78ea8da0f1b947d2bfeea8b357218deb</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">chi</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Chang JIANG</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Lung cancer is one of the most prevalent malignancies with the highest morbidity and mortality rates worldwide. In recent years, with the development of immune-oncology research and several therapeutic antibodies have reach the clinic, many breakthroughs have been made in immunotherapy. The advent of immunotherapy has revolutionized the treatment of NSCLC, but the response and durable clinical benefit are only observed in a small subset of patients. Therefore, strategies to screen the potential beneficial population and improve the efficacy of immunotherapy remain an essential topic. In the current article, the author review the biomarkers that have potential to better predict responders to immunotherapy and to provide ideas for the clinical application of immunotherapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nsclc</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">biomarker</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pd-l1</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">tmb</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ling YI</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xiang GAO</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hongtao ZHANG</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shucai ZHANG</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Chinese Journal of Lung Cancer</subfield><subfield code="d">Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2008</subfield><subfield code="g">25(2022), 1, Seite 46-53</subfield><subfield code="w">(DE-627)572421125</subfield><subfield code="w">(DE-600)2438672-8</subfield><subfield code="x">19996187</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:25</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:46-53</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3779/j.issn.1009-3419.2021.102.55</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/78ea8da0f1b947d2bfeea8b357218deb</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.55</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1009-3419</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1999-6187</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">25</subfield><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="h">46-53</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Chang JIANG
spellingShingle	Chang JIANG misc RC254-282 misc nsclc misc immunotherapy misc biomarker misc pd-l1 misc tmb misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer
authorStr	Chang JIANG
ppnlink_with_tag_str_mv	@@773@@(DE-627)572421125
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	19996187
topic_title	RC254-282 Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer nsclc immunotherapy biomarker pd-l1 tmb
topic	misc RC254-282 misc nsclc misc immunotherapy misc biomarker misc pd-l1 misc tmb misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc RC254-282 misc nsclc misc immunotherapy misc biomarker misc pd-l1 misc tmb misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc RC254-282 misc nsclc misc immunotherapy misc biomarker misc pd-l1 misc tmb misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Chinese Journal of Lung Cancer
hierarchy_parent_id	572421125
hierarchy_top_title	Chinese Journal of Lung Cancer
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)572421125 (DE-600)2438672-8
title	Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer
ctrlnum	(DE-627)DOAJ073516902 (DE-599)DOAJ78ea8da0f1b947d2bfeea8b357218deb
title_full	Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer
author_sort	Chang JIANG
journal	Chinese Journal of Lung Cancer
journalStr	Chinese Journal of Lung Cancer
callnumber-first-code	R
lang_code	chi
isOA_bool	true
recordtype	marc
publishDateSort	2022
contenttype_str_mv	txt
container_start_page	46
author_browse	Chang JIANG Ling YI Xiang GAO Hongtao ZHANG Shucai ZHANG
container_volume	25
class	RC254-282
format_se	Elektronische Aufsätze
author-letter	Chang JIANG
doi_str_mv	10.3779/j.issn.1009-3419.2021.102.55
author2-role	verfasserin
title_sort	research progress of immunotherapy biomarkers for non-small cell lung cancer
callnumber	RC254-282
title_auth	Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer
abstract	Lung cancer is one of the most prevalent malignancies with the highest morbidity and mortality rates worldwide. In recent years, with the development of immune-oncology research and several therapeutic antibodies have reach the clinic, many breakthroughs have been made in immunotherapy. The advent of immunotherapy has revolutionized the treatment of NSCLC, but the response and durable clinical benefit are only observed in a small subset of patients. Therefore, strategies to screen the potential beneficial population and improve the efficacy of immunotherapy remain an essential topic. In the current article, the author review the biomarkers that have potential to better predict responders to immunotherapy and to provide ideas for the clinical application of immunotherapy.
abstractGer	Lung cancer is one of the most prevalent malignancies with the highest morbidity and mortality rates worldwide. In recent years, with the development of immune-oncology research and several therapeutic antibodies have reach the clinic, many breakthroughs have been made in immunotherapy. The advent of immunotherapy has revolutionized the treatment of NSCLC, but the response and durable clinical benefit are only observed in a small subset of patients. Therefore, strategies to screen the potential beneficial population and improve the efficacy of immunotherapy remain an essential topic. In the current article, the author review the biomarkers that have potential to better predict responders to immunotherapy and to provide ideas for the clinical application of immunotherapy.
abstract_unstemmed	Lung cancer is one of the most prevalent malignancies with the highest morbidity and mortality rates worldwide. In recent years, with the development of immune-oncology research and several therapeutic antibodies have reach the clinic, many breakthroughs have been made in immunotherapy. The advent of immunotherapy has revolutionized the treatment of NSCLC, but the response and durable clinical benefit are only observed in a small subset of patients. Therefore, strategies to screen the potential beneficial population and improve the efficacy of immunotherapy remain an essential topic. In the current article, the author review the biomarkers that have potential to better predict responders to immunotherapy and to provide ideas for the clinical application of immunotherapy.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2014 GBV_ILN_2106 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer
url	https://doi.org/10.3779/j.issn.1009-3419.2021.102.55 https://doaj.org/article/78ea8da0f1b947d2bfeea8b357218deb http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.55 https://doaj.org/toc/1009-3419 https://doaj.org/toc/1999-6187
remote_bool	true
author2	Ling YI Xiang GAO Hongtao ZHANG Shucai ZHANG
author2Str	Ling YI Xiang GAO Hongtao ZHANG Shucai ZHANG
ppnlink	572421125
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3779/j.issn.1009-3419.2021.102.55
callnumber-a	RC254-282
up_date	2024-07-03T18:07:43.926Z
_version_	1803582244320706560
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ073516902</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309115427.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2022 xx \|\|\|\|\|o 00\| \|\|chi c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3779/j.issn.1009-3419.2021.102.55</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ073516902</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ78ea8da0f1b947d2bfeea8b357218deb</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">chi</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Chang JIANG</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Lung cancer is one of the most prevalent malignancies with the highest morbidity and mortality rates worldwide. In recent years, with the development of immune-oncology research and several therapeutic antibodies have reach the clinic, many breakthroughs have been made in immunotherapy. The advent of immunotherapy has revolutionized the treatment of NSCLC, but the response and durable clinical benefit are only observed in a small subset of patients. Therefore, strategies to screen the potential beneficial population and improve the efficacy of immunotherapy remain an essential topic. In the current article, the author review the biomarkers that have potential to better predict responders to immunotherapy and to provide ideas for the clinical application of immunotherapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nsclc</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">biomarker</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pd-l1</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">tmb</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ling YI</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xiang GAO</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hongtao ZHANG</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shucai ZHANG</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Chinese Journal of Lung Cancer</subfield><subfield code="d">Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2008</subfield><subfield code="g">25(2022), 1, Seite 46-53</subfield><subfield code="w">(DE-627)572421125</subfield><subfield code="w">(DE-600)2438672-8</subfield><subfield code="x">19996187</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:25</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:46-53</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3779/j.issn.1009-3419.2021.102.55</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/78ea8da0f1b947d2bfeea8b357218deb</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.55</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1009-3419</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1999-6187</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">25</subfield><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="h">46-53</subfield></datafield></record></collection>
score	7.401165

Nicht das Richtige dabei?

Schreiben Sie uns!

Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?